SEE WHO MIGHT BENEFIT FROM GEMTESA

Meet Laura,* a patient who experiences urgency episodes

Age 53
Teacher
Not currently taking OAB medication

Laura, a patient who experiences urgency episodes.

My anxiety about finding a bathroom quickly is causing me to cancel plans and isolate myself.

*Not an actual patient

OAB Presentation and Impact

  • Persistent urgency episodes (3+ months) causing significant disruption in daily activities (work and personal)
  • Increased frequency and average of 3 daily urge urinary incontinence episodes have caused patient to limit water intake
  • Concerned about taking medications that impact existing hypertension
  • Increased anxiety due to fears about locating bathrooms in public settings

OAB Treatment Profile

  • Not previously treated with pharmacologic therapy
  • Currently using adult absorbent briefs

Comorbidities

  • Hypertension

Additional Medications

  • Metoprolol (metabolized by CYP2D6)1,2

Meet Allison,* a patient who experiences urge urinary incontinence

Age 67
Social Worker
Previously treated with mirabegron

Allison, a patient who experiences urge urinary incontinence.

I'm constantly carrying pads and a change of clothes in case I can't make it in time.

*Not an actual patient

OAB Presentation and Impact

  • Suffering from urgency episodes for more than 1 year since stopping treatment
  • Increased depression due to coping with approximately 3 urge urinary incontinence episodes daily
  • Experiences frequent UTIs in addition to her OAB symptoms
  • Expresses interest in improving UUI symptoms

OAB Treatment Profile

  • Previous medication: mirabegron (50 mg, once daily)
    • Side effects: increased blood pressure, headache, UTIs, and nasopharyngitis3

Comorbidities

  • Depression
  • Type 2 diabetes
  • Hypertension
  • Dyslipidemia

Additional Medications

  • Fluoxetine
    (metabolized by CYP2D6)1,2,4
  • Metformin
  • Metoprolol
    (metabolized by CYP2D6)1,2
  • Rosuvastatin

CYP2D6=cytochrome P450 2D6; UTI=urinary tract infection.

Want to see how GEMTESA may be able
to help patients like Laura and Allison?

Pivotal efficacy data

Want to see results from the
52-week extension study?

Extension study data
 

References: 1. Hansten PD, Horn JR. The Top 100 Drug Interactions; A Guide to Patient Management. 2019 ed. Freeland, WA: H&H Publications, LLP; 2019. 2. Kobriger A. Drug Use in Long-Term Care (Effects on Nutrition & Health Status). OnCourse Learning; 2011:i-170. 3. Myrbetriq® (mirabegron extended release tablets) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; 2018. 4. Meeks TW, Culberson JW, Horton MS. Medications in long-term care: when less is more. Clin Geriatr Med. 2011;27(2):171-191. doi:10.1016/j.cger.2011.01.003